The present guidelines aim to provide comprehensive information regarding laboratory diagnosis of Mycoplasma genitalium infections in East European countries. These guidelines are intended primarily for laboratory professionals testing specimens from patients at sexual health care clinics, but may also be useful for community-based screening programmes. Diagnosis of M. genitalium infection is performed exclusively using nucleic acid amplification tests (NAATs), owing to the poor and slow growth of the bacterium in culture. Because no internationally validated and approved commercial NAAT for M. genitalium detection is presently available, it is necessary that laboratories performing M. genitalium diagnostics not only carefully evaluate and validate their in-house PCRs before using them routinely, but also use comprehensive internal controls and take part in external quality assessment programmes. The guidelines were elaborated as a consensus document of the Eastern European Sexual and Reproductive Health Network, and comprise one element of a series of guidelines aimed at optimizing, standardizing, and providing guidance on quality laboratory testing for reproductive tract infections.
Mycoplasma genitalium is a relatively newly discovered microorganism, which was first isolated in 1980 from two of 13 men with non-gonococcal urethritis (1). M. genitalium is a very fastidious bacterium, and cultivation of this organism is exceedingly difficult and time-consuming; therefore data regarding its clinical relevance have become available only after introduction of PCR assays (2, 3) . With the use of PCR tests, it has been shown that M. genitalium is a sexually transmitted pathogen and that the spectrum of diseases in both males and females is similar to that caused by Chlamydia trachomatis and Neisseria gonorrhoeae (4).
In Eastern Europe, the true incidence and prevalence of most sexually transmitted infections (STIs), including M. genitalium infection, remain unknown. This situation results primarily from suboptimal diagnostics, case reporting and surveillance systems (5-11). The present guidelines are the most recent in a series of guidelines (12) (13) (14) (15) developed by the Eastern European Sexual and Reproductive Health (EE SRH) Network (11, 16, 17) aimed at establishing quality laboratory testing for STIs in East European countries. It is envisaged that different countries may need to make minor national adjustments to the guidelines presented here in order to meet local laws, health strategies and the availability of kits and reagents.
CLINICAL PRESENTATION OF M. GENITALIUM INFECTIONS
Considerable evidence has accumulated in recent years to suggest that M. genitalium has an aetiological role in urethritis in males (4 Most of the PCR assays are based on detection of sequences within the MgPa adhesin gene of M. genitalium. Some parts of the MgPa gene, however, are highly variable and primers targeting these regions will not perform well with clinical specimens. In Table I , the maximal number of mismatches found with a single M. genitalium strain in the target region is given for each MgPa gene primer aligned with 22 known sequences. These sequences (n = 22) were obtained from the seven M. genitalium strains deposited in the ATCC with known high sequence homology to the G37 type strain, from an early passage of the M30 strain isolated by David Taylor-Robinson in 1980 (1), from three consecutive isolates from a French patient, and from 11 unrelated M. genitalium strains isolated from patients from Scandinavia and Japan.
The 16S rRNA gene is also used as target in M. genitalium PCRs (46, 48, 52) ; however, owing to the homology between M. genitalium and M. pneumoniae, design of specific and sensitive primers and probes is relatively difficult (45). For some 16S rRNA gene PCR assays, detection of M. genitalium is based on amplification with Mollicutes (Mycoplasma and Ureaplasma) universal primers and subsequent hybridization with species specific probes (50, 51). Although this approach allows detection of several Mycoplasma species from the same primary amplification reaction, significant competition, in particular with amplification of ureaplasmal 16S rRNA gene sequences, can result in poor sensitivity for detection of M. genitalium DNA (55) .
Several real-time M. genitalium PCR tests have been developed since the first real-time assay was published in 2002 by Yoshida et al. (51) . The combination of high sensitivity, specificity, robustness and reduced risk of contamination with amplicons suggests that real-time PCR should be the main method for M. genitalium diagnostics in the future. Quantification of M. genitalium DNA, which is feasible using real-time PCR, may provide important information regarding a number of research questions such as treatment efficacy (53) or clinical relevance of M. genitalium DNA load in clinical specimens (44) .
As an alternative to PCR, a transcription-mediated amplification (TMA) assay targeting the 16S rRNA, a molecule present in up to 100-1000 copies per bacterial cell, thereby increasing the sensitivity of detection compared with the PCR assays that target single-copy genes, has been offered recently (56). This NAAT was shown to be a sensitive, specific and high-throughput test for M. genitalium detection. In Russia, a nucleic acid sequence-based amplification (NASBA) assay (57) also targeting 16S rRNA is commercially available.
Although NAATs are the only effective tools available for detection of M. genitalium at present, and some are commercially available, no approved commercial NAAT is available. It is important to note, that for diagnostic use in the European Union, commercial tests need to be CE (Conformité Européenne) marked according to the In Vitro Diagnostic Medical Devices Directive 98/79/EC. However, in Article 1.5 of the Directive, devices "manufactured and used only within the same health institution and on the premises of their manufacture, or used on premises in the immediate vicinity, without having being transferred to another legal entity" are excluded. This allows in-house NAATs to be used for diagnostic purposes within the institution if this service is provided without a fee or as part of any commercial transaction, but even so, quality assurance is of utmost importance.
INDICATIONS FOR TESTING FOR M. GENITALIUM
The main indications for testing for M. genitalium are presented in Table II .
At present, population screening for M. genitalium is considered premature because prospective data on the natural history of disease, as well as clear evidence regarding M. genitalium as a cause of severe complications and sequelae is lacking (59).
CLINICAL SAMPLES FOR TESTING

General
In recent years, many NAATs have been used to detect M. genitalium in patient specimens (Table I) , and some studies have also assessed the sensitivities of different specimen types for the detection of M. genitalium (52, 56, (60) (61) (62) . In one large study, male first voided urine (FVU) was found to detect more M. genitalium infections (98%) than urethral swabs (82%). In females, however, FVU detected only 71% of the M. genitalium infections, while using both FVU and a cervical swab specimen increased the sensitivity to 96% (60).
In a study by Wroblewski et al. (56) , it was concluded that in women, the most sensitive specimen type for the detection of M. genitalium was a vaginal swab (84% of infections by TMA, 91% by PCR), followed by a cervical swab (60% by TMA, 53% by PCR) and urine (58% by TMA, 65% by PCR). Their findings that vaginal swab specimens are more sensitive than urine specimens for the detection of M. genitalium infection in women differ from those of Shipitsyna et al. (62) , who showed that FVU was superior to both vaginal samples in females (100% vs. 57%) and to urethral swabs in males (83% vs. 75%) for the detection of infection.
Although the ideal genital specimen type for the detection of M. genitalium in men and women has not been thoroughly assessed, FVU seems to be the most sensitive specimen for the detection of M. genitalium infection in men, whereas in women, the use of more than one specimen may significantly improve the diagnostic sensitivity. In a recent study, endocervical swab specimens mixed and transported in FVU demonstrated a trend towards a higher sensitivity than FVU specimens alone as well as a significantly increased sensitivity compared with endocervical swab specimens transported in 2-SP medium for detection of M. genitalium DNA (61). It is important to note, however, that the ideal specimen type is highly dependent on the method applied for nucleic acid extraction and that the optimal specimen type may also differ between NAATs. Unfortunately, no systematic comparative studies on sample preparation before NAAT have been performed, but important issues to consider are: (i) sample collection without unnecessary volumes of transport medium, i.e. avoiding dilution of FVU specimen by mid-stream urine; (ii) concentration of the bacterial cells by centrifugation, and use of methods for purification that yield sufficiently clean nucleic acids without loss of target or excessive number of manipulations that would increase the risk of sample cross-contamination.
Sample collection, transportation and storage
The performance characteristics of the diagnostic tests are largely dependent upon the quality of the sampling. Even the best tests may give inadequate results owing to inappropriate sampling. Ideally, sampling and transport should be identical to that for C. trachomatis NAAT detection as the same specimen is usually tested for both agents. If no transport medium is specified in the manufacturer's instruction, samples may be collected in 2-SP medium (sucrose-phosphate buffer; 0.2 M sucrose, 0.02 M phosphate) according to the following procedures (Table III) . Sample transportation and storage:
clinical materials should be transported to the labora-• tory as soon as possible. if storage conditions are not indicated in the manu-• facturer's instruction, samples should be kept at room temperature for up to 6 h or in a refrigerator for up to one week. Freezing should be avoided if possible as it decreases the sensitivity in most transport media (unpublished data 1 ).
PCR-BASED DIAGNOSIS OF M. GENITALIUM INFECTION
Analysis procedures
All analysis procedures should be performed in accordance with the instructions of the manufacturer of the specific PCR, using equipment, reagents and disposables supplied/ recommended. Each run should include all necessary quality controls: positive (amplification) control, negative (contamination) control, and inhibition control.
PCR tests used in East European countries for diagnosis of M. genitalium infection
The information regarding performance characteristics of NAATs used in East European countries for the detection of M. genitalium is limited, but an evaluation of some commercially available Russian PCRs has recently been published (62). QUALITY ASSURANCE At present, NAATs are the only tools available for M. genitalium detection. A quality assurance scheme for nucleic acid-based diagnostics is presented in Fig. 1 . Prior to implementation in routine diagnostics, methods should be fully evaluated and validated. General guidelines and the minimum requirements for validation of a new or modified test have been published (63, 64) . Based on these principles, for validation of a new test for M. genitalium infection, we recommend:
Validation of the proposed test against an internatio-• nally validated and published test; A minimum of 50 positive clinical specimens and 100 • negative specimens should be tested (as shown by the reference test); Specimens that are weakly positive should be inclu-• ded. Replicate dilutions of a strong positive specimen should also be included to assess the reproducibility of detection at low copy number; The sensitivity of the proposed test should not be more • than 5% below that of the chosen reference test and the specificity should be > 99%.
Recently, a series of studies has been conducted in Russia to evaluate NAATs used for diagnosis of STIs, including M. genitalium infection (62, 65, 66) . The diagnostic performance of the M. genitalium PCRs displayed a high level of concordance with the reference assays, but the results of the study indicated that only one of the five PCRs evaluated had a reasonable clinical sensitivity, whereas the specificities of all the tests were high.
RECOMMENDATIONS
A diagnosis of • M. genitalium infection should be performed exclusively using NAATs, owing to the poor and slow growth of the bacterium in culture. Since no internationally validated and approved • commercial NAATs for M. genitalium detection are presently available, it is necessary that laboratories performing M. genitalium diagnostics carefully evaluate and validate in-house PCRs before using them in routine clinical practice. Comprehensive internal controls should be used and laboratories should participate in external quality assessment programmes.
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Males
Urethral swab
In case of abundant discharge clean the external opening with a cotton (gauze) swab Introduce a sampling swab into the urethral meatus (0.5-2 cm), slightly rotate the swab in the urethra for few seconds, then take it out and place into a tube with transport medium First catch urine Ask the patient to collect the first 5-10 ml of the freely voided urine without previous washing Females Cervical swab Introduce warmed gynaecological speculum and clean the external cervical os to remove contaminating vaginal discharge using a large cotton (gauze) swab Introduce a sampling swab into the endocervical canal (1-2 cm), slightly rotate the swab inside the endocervical canal, then take it out and place into a tube with transport medium
In case of abundant discharge clean the external opening with a cotton (gauze) swab Introduce a sampling swab into the urethral meatus (0.5-2 cm), slightly rotate the swab in the urethra for few seconds, then remove it and place into a tube with transport medium
Vaginal swab
Obtain material under direct vision using a gynaecological speculum from the posterior and lateral fornices of the vagina using a sterile swab, then place it into a tube with transport medium Self-obtained vaginal swabs can be used in certain situations. Women are instructed to insert the swab approximately 5 cm into the vagina and rotate three times. The procedure should not elicit any pain. After retraction, the swab is placed in an appropriate transport medium
First catch urine
Ask the patient to collect the first 5-10 ml of the first voided urine without any previous washing Fig. 1 . A quality assurance scheme in diagnostic microbiology using nucleic acid amplification tests. 
